CUTISS attracts CHF 25 million and enters Phase 3 clinical trials

CUTISS AG, a Swiss pioneering life sciences company specializing in skin regenerative medicine and tissue engineering, announced the first closing of CHF 25 million in its Series C funding round. To date, CUTISS has raised a total of CHF 92 million from private investors, family offices, and public bodies.

CUTISS develops the first-in-class personalized and automated skin tissue therapy offering life-saving and life-changing medical treatments for patients with severe skin injuries globally. This first closing allows CUTISS to enter Phase 3 clinical trials for its personalized skin therapy denovoSkin, which recently announced positive results in Phase 2. Additionally, funds will be used to advance the industrialization and clinical readiness of the automated machine for bioengineering denovoSkin, and to finalize pre-launch activities for the commercialization of VitiCell, a medical device for Vitiligo treatment in-licensed from IBSA Pharma.

The Series C round is co-led by the family office of Giammaria Giuliani, a longstanding lead investor, and a new co-lead investor, a US family represented by Shiloh Advisors AG. The company continues to welcome new investors to join its journey towards commercialization. 

Daniela Marino, CEO and co-founder of CUTISS, commented: “Securing the first CHF 25 million in our Series C funding round is a pivotal achievement for CUTISS. We deeply appreciate the trust and support of our existing and new investors. This funding will enable us to continue working at speed to reach our critical development milestones and bring our life-changing treatments to patients in need. The recent positive Phase 2 clinical trial results for denovoSkin have fueled our determination to innovate further in regenerative medicine.” In February CUTISS announced positive one-year follow-up data from its Phase 2 clinical trial of the lead product denovoSkin, in adult and adolescent severe burn patients. Following the announced positive primary endpoint in Q1 2023, the one-year readout evaluated long term safety and scar quality. 

Established in 2017, the company is a spin-off from University of Zurich (UZH) / University Children’s Hospital. The company is based at the Bio-Technopark in Zurich-Schlieren.

(Press release / SK)